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Abstract 24 
 Diabetes mellitus (DM) can result in cardiovascular dysfunction and heart failure 25 
characterized by diastolic dysfunction with or without the presence of systolic dysfunction in 26 
people and laboratory animals. The objective of this prospective study was to determine if cats 27 
with newly diagnosed DM had myocardial dysfunction and, if present, whether it would progress 28 
if appropriate antidiabetic therapy was commenced. Thirty-two diabetic cats were enrolled and 29 
received baseline echocardiographic examination; of these, 15 cats were re-examined after 6 30 
months. Ten healthy age- and weight-matched cats served as controls.  31 
 32 
 Diabetic cats at diagnosis showed decreased diastolic, but not systolic function, when 33 
compared to healthy controls, with lower mitral inflow E wave (E) and E/E’ than controls. After 34 
6 months, E and E/IVRT’ decreased further in diabetic cats compared to the baseline evaluation. 35 
After excluding cats whose DM was in remission at 6 months, insulin-dependent diabetic cats 36 
had lower E, E/A and E’ than controls. When classifying diastolic function according to E/A and 37 
E’/A’, there was shift towards impaired relaxation patterns at 6 months. All insulin-dependent 38 
diabetic cats at 6 months had abnormal diastolic function. These results indicate that DM has 39 
similar effects on diastolic function in feline and human diabetics. The dysfunction seemed to 40 
progress rather than to normalize after 6 months, despite antidiabetic therapy. In cats with pre-41 
existing heart disease, the development of DM could represent an important additional health 42 
risk. 43 
 44 
Keywords: Cats; Diabetes mellitus; Diastolic function; Echocardiography; Tissue Doppler 45 
imaging 46 
3	
	
  47 
4	
	
Introduction 48 
 In humans, the concept of diabetic angiopathy was originally suggested in 1954 49 
(Lundbaek, 1954) and diabetic cardiomyopathy was first described in 1972 (Rubler et al., 1972). 50 
More recently, researchers have demonstrated that diabetes mellitus (DM) is an independent risk 51 
factor for the development of heart failure (Kannel et al., 1974; Aronow and Ahn, 1999; 52 
Gottdiener et al., 2000). Patients with DM and concomitant cardiovascular disease have a poorer 53 
prognosis compared to those with only cardiovascular disease (Stone et al., 1989). Additionally, 54 
type 2 human diabetics commonly have left ventricular diastolic dysfunction without clinically 55 
detectable heart disease (Poirier et al., 2001). Recently, diabetic cardiomyopathy has been 56 
defined as the existence of left ventricular dysfunction in diabetic patients without coronary 57 
artery disease, hypertension or other potential causes (Ernande and Derumeaux, 2012).  58 
 59 
 Few studies have examined the existence of cardiovascular consequences of DM in 60 
veterinary medicine. One study found congestive heart failure (CHF) to be the most commonly 61 
associated condition in cats with hyperglycemia (Laluha et al., 2004). In that study, CHF was 62 
considered the primary condition and stress hyperglycemia was concurrent. However, that study 63 
could not determine if in individual cases hyperglycemia was due to recently developed DM and 64 
was potentially the cause of acute CHF in previously unrecognized stable heart disease (Laluha 65 
et al., 2004). Heart disease and CHF was common in diabetic cats in another study (Little and 66 
Gettingby, 2008), but those cats had a range of cardiac disorders and causal relationships were 67 
not established. Importantly, cardiac function has never been specifically studied in cats with 68 
DM.  69 
 70 
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 We sought to assess cardiac function in feline patients with newly diagnosed DM and to 71 
characterize the further development over the course of 6 months. We hypothesized that cats 72 
with DM would show evidence of cardiac dysfunction at the time of diagnosis, which would 73 
normalize over time with successful antidiabetic therapy.  74 
 75 
Materials and methods 76 
Inclusion and exclusion criteria, diabetic cats and control cats  77 
 Cats presenting to the Clinic for Small Animal Internal Medicine of the University of 78 
Zurich with spontaneously occurring DM, newly diagnosed or diagnosed within the previous 4 79 
weeks, were prospectively enrolled in the study. Cats were excluded if they had structural heart 80 
disease, or concomitant systemic disease that might affect cardiac function, such as 81 
hypersomatotropism, hyperthyroidism, systemic hypertension (defined as systolic blood pressure 82 
>160 mmHg; Brown et al., 2007), severe anemia (defined as haematocrit <18%; Wilson et al., 83 
2010), recent glucocorticoid treatment (Smith et al., 2004), or severe underlying disease that was 84 
expected to complicate diabetic control or markedly shorten life expectancy. Blood pressure was 85 
measured using either the indirect Doppler technique (Ultrasound Doppler Flow Detector, Parks 86 
Medical Electronics) or an oscillometric device (HDO Vet Blood Pressure Monitor, DVM 87 
Solutions) after a short adaptation period in a quiet environment (Brown et al., 2007). The lowest 88 
and highest of at least five consecutive measurements were excluded and an average value was 89 
then calculated.  90 
 91 
 All cats underwent physical examination, complete blood count, biochemical profile, 92 
urinalysis (including protein-creatinine ratio and bacterial culture), serum fructosamine, beta-93 
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hydroxybutyrate, feline pancreatic lipase immunoreactivity, thyroxine (T4) and insulin-like 94 
growth factor 1, thoracic and abdominal radiographs and abdominal ultrasound. Additionally, 95 
cats underwent CT when deemed necessary to corroborate hypersomatotropism. The standard 96 
antidiabetic therapy included insulin glargine twice daily, and a low carbohydrate, high protein 97 
diet (Purina DM, Société des Produits Nestle). Additionally, six cats received an extended-98 
release glucagon-like peptide-1 (GLP-1) analogue, exenatide, as part of another study (Riederer 99 
et al., 2014). Diabetic remission during the course of the study was deﬁned as being clinically 100 
unremarkable, and maintaining normal blood glucose and fructosamine concentrations without 101 
insulin therapy for at least 1 month after cessation of treatment (Sieber-Ruckstuhl et al., 2008; 102 
Zini et al., 2010). Echocardiographers were masked to each cat’s diabetic control status at the 6-103 
month examination. Ten healthy age- and weight-matched cats, imaged during the same period, 104 
served as controls. The study was approved by the State Veterinary Ofﬁce of Zurich (Application 105 
numbers 122/2011, approved July 7, 2011, and 118/2014, approved June 17, 2014). 106 
 107 
Echocardiography 108 
 Recruited cats underwent echocardiography, unsedated, by a board-certified cardiologist 109 
or a cardiology resident at the time of diagnosis (DM0), followed by a re-evaluation at 6 months 110 
post-diagnosis (DM6) after they had been rehydrated (if considered dehydrated at presentation). 111 
Dehydration was estimated at admission and corrected over the first 12 h; when rehydrated, fluid 112 
rate was decreased to maintenance rate (3 mL/kg/h). Examinations were performed with a Vivid 113 
7 (GE Medical Systems) using a 7S or a 10S probe, with simultaneous ECG acquisition. 114 
Echocardiographic planes were acquired according to published guidelines (Thomas et al., 115 
1993). Quantitative 2-dimensional (2D) data from right parasternal views included long axis left 116 
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atrial diameter (LAD), and short axis left atrial to aortic diameter ratio (LA/Ao), M-Mode short 117 
axis interventricular septum thickness in diastole (IVSd), left ventricular internal diameter in 118 
diastole (LVIDd), left ventricular free wall in diastole (LVFWd) and left ventricular fractional 119 
shortening (FS). Absence of structural heart disease was defined as qualitatively normal 120 
appearance of all four chambers on 2D echocardiography, and quantitatively normal left atrial 121 
size (2D LA/Ao in short axis < 1.5) and normal LV wall thickness in diastole (2D or M-Mode 122 
<5.5 mm; Christiansen et al., 2015). 123 
 124 
 Quantitative pulsed wave (PW) Doppler and tissue Doppler imaging (TDI) variables 125 
were recorded from the left apical four chamber view and included mitral inflow E (E) and A (A) 126 
waves, E/A ratio (E/A), TDI isovolumic relaxation time (IVRT’), E to IVRT’ ratio (E/IVRT’), 127 
TDI systolic wave (S’), TDI early (E’) and atrial diastolic wave (A’), E'/A' ratio (E'/A'), and E to 128 
E’ ratio (E/E’). For E and A wave velocities, a PW sample volume of 2 mm was placed between 129 
the tips of the opened mitral valve leaflets as previously described (Schober and Chetboul, 2015). 130 
The E/A was not calculated when the E and A were completely or partially fused (E-at-A 131 
velocity > 20 cm/s; Schober et al., 2003). The TDI variables were recorded at the level of the 132 
mitral valve annulus of the left ventricular free wall. IVRT’ was defined as the period between 133 
the end of the S' to the beginning of the E' with a PW sample volume of 1 mm (Koffas et al., 134 
2006); E/A, E/E’ and E/IVRT’ were subsequently calculated. Sweep speed during analysis was 135 
200 mm/s.  136 
 137 
 Diastolic function was classified according to mitral Doppler inflow and TDI 138 
measurements into normal (E/A 1-2 and E'/A' >1), delayed relaxation (E/A <1 and E'/A' <1), 139 
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pseudonormal (E/A 1-2, E'/A' <1) or restrictive (E/A >2 and E'/A' <1) patterns (Schober and 140 
Chetboul, 2015). Systolic function was assessed using FS and S´. 141 
 142 
Statistical analysis 143 
 Data were analysed for normality using the Shapiro-Wilk test at an α level of 0.05. Mean 144 
and standard deviation for individual echocardiographic variables were then calculated. A two 145 
sample t-test was performed to compare diabetic cats at the time of diagnosis and control cats. A 146 
paired sample t-test was used to compare diabetic cats at the time of diagnosis and at 6 months 147 
post-diagnosis. Calculations were performed initially by including cats in diabetic remission at 6 148 
months, and then by excluding these cats at both time points (DM0nr, diabetics at time of 149 
diagnosis excluding those with DM in remission at 6 months; DM6nr, diabetics at 6 months post-150 
diagnosis excluding those with DM in remission; DM0r, diabetics at the time of diagnosis that 151 
progressed to diabetic remission; DM6r, diabetics in remission at 6 months post-diagnosis). 152 
Comparison of diastolic function patterns between and within groups was performed using Chi-153 
square and McNemar analysis, respectively. The effect of age on parameters of diastolic function 154 
was calculated using the Pearson correlation test. Cats with fused E waves were excluded from 155 
all analyses. Statistical significance was set at P <0.05 for all comparisons. Data are presented as 156 
mean ± standard deviation [range]. Graphs and statistical analyses were performed using 157 
commercially available software (SPSS Statistics, IBM). 158 
 159 
Results  160 
 Between May 2013 and October 2014, 50 cats were screened for inclusion. Eighteen cats 161 
were subsequently excluded for the following reasons: evidence of structural heart disease (n=4; 162 
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two of these cats developed dyspnea at presentation to the hospital and showed radiographic 163 
evidence of CHF and echocardiographic evidence of left ventricular hypertrophy); DM due to 164 
hypersomatotropism (n=3); DM of >4 weeks duration (n=2); clinical signs and findings 165 
consistent with severe pancreatitis (n=2); evidence of neoplastic disease (n=2); severe anemia 166 
(n=1); hyperthyroidism (n=1); hypertension (n=1); cholecystitis (n=1); and asthma (n=1). 167 
 168 
 The remaining 32 cats were included in the study. The study population included Maine 169 
Coon (n=2), Norwegian Forest (n=2) and Domestic short haired (DSH) cats (n=28); 18 were 170 
female and 14 were male. Cats were 10.8 ± 3.4 [4-19] years old and weighed 4.97 ± 1.27 [3.0-171 
7.7] kg. All cats were treated with glargine and six cats were also treated with GLP-1. The ten 172 
control cats were DSH (n=4), Maine Coon (n=2), Domestic longhair (n=1), Bengal (n=1), 173 
Burmese (n=1) and Persian (n=1), aged 9.2 ± 4.3 [3-17] years and weighing 4.17 ± 1.07 [3-6.3] 174 
kg. Diabetic and control cats did not differ in age (P=0.216), bodyweight (P=0.08) or blood 175 
pressure measurements (P=0.89). 176 
 177 
 Fifteen of the 32 diabetic cats included in the study presented to the 6 month recheck 178 
examination. Of the 17 cats that failed to present at 6 months, five died (undiagnosed causes, 179 
n=4; diabetic ketoacidosis, n=1); three owners declined follow up appointments; and the 180 
remaining nine were lost to follow up. Of the 15 cats remaining in the study, five were in 181 
diabetic remission at 6 months. Of the six cats receiving GLP-1 at inclusion, five were followed 182 
up at 6 months (three underwent remission).  Fructosamine concentrations were as follows: DM0 183 
– 623 ± 98 [418 - 775] µmol/L; DM6 – 377 ± 122 [256 - 616] µmol/L; DM6nr – 405 ± 112 [258 - 184 
616] µmol/L; DM6r – 279 ± 28 [256 - 330] µmol/L (reference interval: 200 – 340 µmol/L).  185 
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 186 
 No differences were observed in 2-D and M-Mode parameters between the groups at 187 
baseline (Table 1). No cat exhibited abnormalities in systolic function, quantified by M-Mode FS 188 
and pulsed-wave Doppler tissue imaging (PWDTI) S’, at any time. Age did not correlate with 189 
any echocardiographic variables. Assessment of both E/A and E'/A' was possible for five control 190 
cats, 23 diabetic cats at diagnosis, 12 cats at 6 months and seven cats at 6 months, after excluding 191 
cats in remission. In the other cats, these variables could not be measured, because of fused E 192 
and A waves. At diagnosis, diabetic cats had lower E (P=0.008) and E/E´ (P=0.04) than control 193 
cats (Table 1). At 6 months, diabetic cats had lower E (P=0.005), E/IVRT’ (P=0.12) and heart 194 
rate (P=0.11) than at baseline (Table 1). Diabetic cats that failed to undergo remission at 6 195 
months (DM6nr) had lower E velocities (P=0.022), E/A (P=0.029), and E' velocities (P=0.018) 196 
than control cats and lower E’ (P=0.003), E’/A’ (P=0.23) and higher E/E’ (P=0.034) than 197 
diabetic cats that underwent remission (DM6r; Table 1). 198 
 199 
 Abnormal diastolic function patterns were more prevalent in diabetic cats at 6 months 200 
(DM6; P=0.013) and diabetic cats not in remission (DM6nr; P=0.006) than in control cats (Table 201 
2). Of the cats that did not undergo diabetic remission, one that initially had a normal diastolic 202 
function pattern progressed to a delayed relaxation pattern at 6 months, and three other cats that 203 
initially had delayed relaxation progressed to a pseudonormal pattern. Of the cats that underwent 204 
diabetic remission (DM6r), one that initially had normal function remained normal; two that 205 
initially had normal function developed delayed relaxation patterns; and one that initially had a 206 
pseudonormal pattern reverted to a delayed relaxation pattern (Fig. 1). None of the cats showed a 207 
restrictive pattern of diastolic function (Table 2).  208 
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 209 
Discussion 210 
 This is the first study to specifically evaluate cardiac function in diabetic cats, and our 211 
results suggest that DM affects diastolic cardiac function. This dysfunction is apparent in cats 212 
prior to instituting antidiabetic therapy, and persists or progresses in cats that fail to undergo 213 
remission after 6 months of therapy, but possibly improves in cats that undergo remission. 214 
 215 
 In humans, diabetic cardiomyopathy is defined as the presence of cardiac dysfunction in 216 
diabetic patients, when other causes of heart disease such as coronary artery disease or systemic 217 
hypertension have been excluded (Ernande and Derumeaux, 2008). Several predisposing factors 218 
have been suggested for human diabetic cardiomyopathy, e.g., severe coronary atherosclerosis 219 
and prolonged hypertension. However, the recent definition of diabetic cardiomyopathy excludes 220 
these factors (Ernande and Derumeaux, 2008). The following pathogenic factors are currently 221 
implicated: chronic hyperglycaemia, microvascular disease (Shapiro et al., 1981), glycosylation 222 
of myocardial proteins, autonomic neuropathy (Grundy et al., 1999; Fang et al., 2004; Maisch et 223 
al., 2011; Amaral and Okonko, 2015) and altered cellular calcium handling (Allo et al., 1991; 224 
Pierce and Russel, 1997; Belke and Dillmann, 2004). Additionally, increased concentrations of 225 
free fatty acids, leading to accelerated fat metabolism and development of reactive oxygen 226 
species, have been suggested as pathogenic factors (Boudina and Abel, 2007). Experimentally, 227 
uncontrolled DM produces progressive myocardial damage consisting of loss of myofibrils and 228 
mitochondria, deposition of extracellular matrix and decrease of capillary density, that can only 229 
partially be reversed by insulin treatment (Thompson et al., 1994). At a molecular level, defects 230 
in calcium movement by various transporters with abnormal cytosolic calcium regulation, and a 231 
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reduction in sarcoendoplasmic reticulum calcium ATPase activity have also been reported (Allo 232 
et al., 1991). Abnormal calcium handling is not only responsible for abnormal contractile and 233 
diastolic function, but increased intracellular free calcium could also be responsible for 234 
cardiomyocyte damage (Pierce and Russel., 1997; Belke and Dillmann, 2004). 235 
 236 
 Distinct phenotypes in diabetic cardiomyopathy have been proposed (dilated phenotype 237 
with reduced ejection fraction and restrictive phenotype with preserved ejection fraction), but it 238 
is not completely clear whether they represent different pathophysiological mechanisms or 239 
simply different stages of the same disease process, with early diastolic dysfunction preceding 240 
systolic dysfunction (Schannwell et al., 2002; Teupe and Rosak, 2012; Pham et al., 2015; 241 
Seferovic and Paulus, 2015).  Experimentally, systolic and diastolic dysfunction characterized by 242 
reduced FS and reduced E/A were found in 12-week old transgenic diabetic mice. These results 243 
were considered evidence of diabetic cardiomyopathy caused by altered cardiac metabolism 244 
(Semeniuk et al., 2002).  245 
 246 
 In small animals, few studies have looked at the association between DM and 247 
cardiovascular disease and their potential effects on cardiac function. Heart murmurs or gallop 248 
rhythms have been observed in approximately 25% of diabetic cats, but specific cardiac 249 
abnormalities were not reported (Crenshaw and Peterson, 1996; Nelson et al., 2000). However, 250 
heart murmurs are also common in healthy cats and heart disease can be present in cats without 251 
audible heart murmurs (Côté et al., 2004; Paige et al., 2009; Nakamura et al., 2011). 252 
Additionally, previous studies have reported the development of CHF in diabetic feline patients 253 
(Rush et al., 2002; Koenig et al., 2004). A more recent retrospective study reported that CHF was 254 
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common among diabetic cats. Diabetic cats had a 10-fold increased risk of CHF compared to 255 
age-matched control cats, and of 14 diabetic cats, CHF was the reason for euthanasia in six. 256 
However, primary heart disease was probably present in these cats, specifically hypertrophic 257 
cardiomyopathy in three, and it is not known if CHF was a diabetic complication or vice versa 258 
(Little and Gettingby, 2008).  259 
 260 
 In our study, cats with evidence of concomitant structural heart disease, such as HCM, 261 
were excluded, to rule-out visible underlying heart disease as cause of dysfunction. We did not 262 
identify evidence of systolic dysfunction in any cats. However, we frequently observed left 263 
ventricular diastolic dysfunction at the time of diagnosis. Furthermore, diastolic dysfunction 264 
seemed to progress rather than normalize over time, despite antidiabetic therapy, in cats that did 265 
not undergo remission. The simultaneous decrease in E and E/E' could be explained by 266 
relaxation abnormalities or decreases in left ventricular filling pressures, potentially due to 267 
polyuria/polydipsia and/or variable states of dehydration, hypovolemia or shock in diabetic cats 268 
at presentation. Volume depleted cats would also be expected to have decreased end diastolic 269 
pressures and therefore increased left ventricular and atrial compliance, leading to a decrease in 270 
E wave measurements (Schober et al., 2003). Hypovolemia should not have been an important 271 
cause of measurement error in this study because in order to avoid dehydration as confounding 272 
factor, we only performed echocardiography when cats were considered rehydrated. However, 273 
even at 6 months, we cannot exclude the possibility that DM6nr had a different hydration status 274 
than DM6r. 275 
 276 
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 Our findings agree with reports in humans. In one study, left ventricular diastolic 277 
dysfunction was considered common in type 2 diabetic patients who had been stable for a 278 
minimum of 3 months, without any clinically detectable heart disease. Diastolic dysfunction 279 
affected 60% of these patients; 28% showed a pseudonormal pattern and 32% a delayed 280 
relaxation pattern (Poirier et al., 2001). Similarly, we identified diastolic dysfunction in 82% 281 
(n=10) of DM6 cats; there was a delayed relaxation in seven cats and a pseudonormal pattern in 282 
three cats. Further, all cats in the DM6nr group showed either persistent or progressive diastolic 283 
dysfunction; five had delayed relaxation and two had pseudonormalization. In another study, 284 
recently diagnosed human type 2 diabetics had preclinical E and E/A abnormalities (Robillon et 285 
al., 1994). We also identified lower E velocities in the DM6 group, as well as lower E/A and E´ 286 
in the DM6nr group.  287 
 288 
 In diabetic humans, a relationship between glycemic control and risk of developing heart 289 
failure has been established (Iribarren et al., 2001); even acromegalic patients undergoing 290 
surgical therapy and subsequent improvement in glycemic control improve their diastolic 291 
functional class (Minniti et al., 2001). Accordingly, optimal glycemic control is considered an 292 
important tool to prevent or mitigate the development of diabetic cardiomyopathy (Grundy et al., 293 
1999). Similarly, glycemic control appears to have influenced our results. In our study, 33% of 294 
diabetic cats underwent remission, while in persistently diabetic cats, insulin treatment had the 295 
intended metabolic effects, as evidenced by normalization of clinical signs, lowering of serum 296 
glucose and decrease in fructosamine concentrations over the 6 months observation period. 297 
However, the DM6nr group had more abnormal diastolic function than the DM6r group, including 298 
higher E´, E´/A´ and reduced E/E´, suggesting improvement of diastolic function and lower LV 299 
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filling pressures in the absence of DM.  Importantly, correction of metabolic derangements with 300 
insulin in the DM6nr group did not necessarily improve diastolic function, as evidenced by 301 
persistent dysfunction compared with baseline measurements and with control cats. 302 
 303 
 The non-normalized fructosamine concentrations in some of the DM6nr group at 6 months 304 
imply that diabetic control was not perfect, which might explain why diastolic dysfunction 305 
progressed despite therapy. Without an untreated diabetic control group, we cannot know if cats 306 
not receiving therapy would have progressed more rapidly or severely into a more advanced 307 
stage of diastolic dysfunction, or even have developed systolic dysfunction, and eventually CHF. 308 
However, it would be unethical not to treat diabetic cats with insulin.  309 
 310 
 This study had several limitations. The number of cats enrolled and in particular, the 311 
number of cats followed up at 6 months, was small, and the timespan of our observation period 312 
was relatively short. Therefore, it is possible that more subtle changes in diastolic variables, 313 
especially in the DM6r group, might have gone undetected. Pulmonary vein flow and color M-314 
mode flow propagation velocities were not measured, and could have provided additional 315 
information to help classify diastolic function (Schober et al., 2003). Essentially, every cat had 316 
been receiving fluids as supportive therapy. Hydration status clearly affects morphological 317 
dimensions and systolic and diastolic echocardiographic parameters of cardiac function (Schober 318 
et al, 2003; Campbell and Kittleson, 2007). Even though at the time of echocardiography all cats 319 
were considered euvolemic, and fluids were given at maintenance rates at the time of initial 320 
echocardiography, the assessment of hydration status is subjective and not exact. Interestingly, 321 
the borderline high LA diameter in one cat suggest mild volume overload. Some cats were 322 
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concurrently enrolled in a study assessing the effect of a GLP-1 analogue on glycemic control. 323 
The cardiovascular effects of GLP-1 agonists are not well studied in cats. In dogs with pacing-324 
induced dilated cardiomyopathy, recombinant GLP-1 led to a significant increase in LV ejection 325 
fraction, cardiac output and lowering of systemic vascular resistance (Nikolaidis et al., 2004). 326 
GLP-1 seems to be cardio protective, potentially augmenting myocardial contractility under 327 
conditions of metabolic stress, with stimulation of myocardial glucose uptake as one major 328 
underlying mechanism (Grieve et al., 2009). GLP-1 and analogues have also been demonstrated 329 
to have a direct vasorelaxant action (Treiman et al., 2010). We cannot exclude the possibility that 330 
the GLP-1 analogue led to masking of underlying systolic dysfunction or altered diastolic 331 
function. Finally, we do not know the duration of diabetes in enrolled cats at the time of 332 
diagnosis. Obviously, in order for DM to affect cardiac function, a certain time span of 333 
uncontrolled glucose metabolism is necessary. Extrapolations from an experimental study in 334 
mice suggest a few weeks is sufficient (Semeniuk et al., 2002). Diabetes can have an insidious 335 
onset, and it seems likely that in our cats DM was present for at least a few weeks.  336 
 337 
Conclusions 338 
 Our results suggest that diastolic dysfunction is common in diabetic cats at the time of 339 
diagnosis, and over the following 6 months an increase in the prevalence of diastolic dysfunction 340 
can occur, despite antidiabetic therapy. These observations indicate that diabetic cardiomyopathy 341 
might be an entity in cats, similar to in humans. Whether the dysfunction identified here becomes 342 
clinically apparent, or exacerbates pre-existing, coincidental cardiac disease, is unknown. 343 
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